How many insider trades does FilingIQ track for NRSN?

FilingIQ tracks 3 Form 4 insider transactions for NRSN (NeuroSense Therapeutics Ltd.), covering filings from Mar 26, 2026 onwards. 3 of those were filed in the last 90 days.

Are NRSN insiders net buyers or net sellers?

Across the full Form 4 history for NRSN, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NRSN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NRSN in?

NeuroSense Therapeutics Ltd. (NRSN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $24.41M.

NRSN insider trading

NasdaqCM Healthcare

NeuroSense Therapeutics Ltd. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$24.41M

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Company website: www.neurosense-tx.com

NRSN insider activity at a glance

FilingIQ has scored 3 insider transactions for NRSN since Mar 26, 2026. The most recent filing in our index is dated Mar 26, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live NRSN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for NRSN?: FilingIQ tracks 3 Form 4 insider transactions for NRSN (NeuroSense Therapeutics Ltd.), covering filings from Mar 26, 2026 onwards. 3 of those were filed in the last 90 days.
Are NRSN insiders net buyers or net sellers?: Across the full Form 4 history for NRSN, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NRSN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is NRSN in?: NeuroSense Therapeutics Ltd. (NRSN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $24.41M.

Methodology & sources

Every NRSN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.